Myopia Control Combined PBM With Myopic Defocus Lens in Children
Myopia, Progressive
About this trial
This is an interventional treatment trial for Myopia, Progressive
Eligibility Criteria
Inclusion Criteria: Informed consent by the supervision of the children 6~13 years old (including both the 6 and 13) SE range: -0.50~-5.50D Astigmatism <=2.00D BCVA >=0.8 Anisometropia <=1.50D Confirmed to no use of other myopia control intervention Exclusion Criteria: Ocular lesions to effect vision or diseases (such as cataract, glaucoma, marcular pathology, cornea lesions, uveitis, retina detachment, congential opitc abnormal and etc.) Halo, glare, toutic, ADHD, psoriasis Systom disease: immune disease, central nerve system, Down syndrome, asthma, severe cardiopulmonary abnormal, severe liver and renal dysfunction. Squint, ocular lesion or acute imflammation. Other myopia control interventions within recent 3 month such as atropine, device, orthokeratology, multi-focus soft lens, multi-function spectacles.
Sites / Locations
- the first people's hospital of XuzhouRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Placebo Comparator
PBM therapy + SVS
Peripheral defocus spectacles
PBM +Peripheral defocus spectacles
Control
Low lever red light therapy with single vision spectacles
a spectacles with special design with peripheral myopic defocus to control myopia progression
Low lever red light therapy with a spectacles with special design with peripheral myopic defocus to control myopia progression
single vision spectacles only as the control